Introduction:
PCI Pharma Services plans for the expansion of manufacturing facility with the addition of world-class facilities. The facility will be located at Bedford, USA.
Features:
The new manufacturing facility will be constructed with an area covering 50,000 square foot to increase breadth of services as a global CDMO. It helps in providing high-volume lyophilisation, liquid filling, and multi-product handling from one format to another.
The facility consists of state of the art technology, along with aseptic fill-finish line accomplished with a fully isolated containment system. In addition, the facility is also equipped with twin lyophilisers with both auto-loading and unloading systems having the capacity to complete 400 vials per minute on a sterile fill-finish line, allowing to reach market faster and helping these therapies to reach patients earlier.
The expansion enhances the capabilities and capacity in aseptic liquid fill-finish and sterile lyophilisation technology, the most important manufacturing process commonly used with injectable and biologic therapies.
Specifications:
| Name | PCI Pharma Services |
| Type | New Construction |
| Budget | US$100 million |
